Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.37
NSPH's Cash to Debt is ranked lower than
59% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.28 vs. NSPH: 1.37 )
Ranked among companies with meaningful Cash to Debt only.
NSPH' s 10-Year Cash to Debt Range
Min: 0.2  Med: 10.19 Max: No Debt
Current: 1.37
Equity to Asset 0.50
NSPH's Equity to Asset is ranked lower than
70% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. NSPH: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
NSPH' s 10-Year Equity to Asset Range
Min: -5.28  Med: 0.85 Max: 0.94
Current: 0.5
-5.28
0.94
F-Score: 4
Z-Score: -14.52
M-Score: -2.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -188.94
NSPH's Operating margin (%) is ranked lower than
78% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. NSPH: -188.94 )
Ranked among companies with meaningful Operating margin (%) only.
NSPH' s 10-Year Operating margin (%) Range
Min: -2890.06  Med: -1399.68 Max: -263.75
Current: -188.94
-2890.06
-263.75
Net-margin (%) -199.09
NSPH's Net-margin (%) is ranked lower than
80% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.79 vs. NSPH: -199.09 )
Ranked among companies with meaningful Net-margin (%) only.
NSPH' s 10-Year Net-margin (%) Range
Min: -4551.67  Med: -1079.05 Max: -273.41
Current: -199.09
-4551.67
-273.41
ROE (%) -183.57
NSPH's ROE (%) is ranked lower than
89% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. NSPH: -183.57 )
Ranked among companies with meaningful ROE (%) only.
NSPH' s 10-Year ROE (%) Range
Min: -2988.54  Med: -76.72 Max: -40.32
Current: -183.57
-2988.54
-40.32
ROA (%) -87.73
NSPH's ROA (%) is ranked lower than
83% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.05 vs. NSPH: -87.73 )
Ranked among companies with meaningful ROA (%) only.
NSPH' s 10-Year ROA (%) Range
Min: -466.5  Med: -68.44 Max: -34.8
Current: -87.73
-466.5
-34.8
ROC (Joel Greenblatt) (%) -252.16
NSPH's ROC (Joel Greenblatt) (%) is ranked lower than
70% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. NSPH: -252.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NSPH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -733.73  Med: -528.37 Max: -314.3
Current: -252.16
-733.73
-314.3
Revenue Growth (3Y)(%) 36.70
NSPH's Revenue Growth (3Y)(%) is ranked higher than
94% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. NSPH: 36.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NSPH' s 10-Year Revenue Growth (3Y)(%) Range
Min: -72.9  Med: -7.50 Max: 50
Current: 36.7
-72.9
50
EBITDA Growth (3Y)(%) -21.00
NSPH's EBITDA Growth (3Y)(%) is ranked lower than
77% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. NSPH: -21.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NSPH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -35.60 Max: 34.7
Current: -21
0
34.7
EPS Growth (3Y)(%) -20.70
NSPH's EPS Growth (3Y)(%) is ranked lower than
71% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. NSPH: -20.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NSPH' s 10-Year EPS Growth (3Y)(%) Range
Min: -69.8  Med: -24.25 Max: 48.1
Current: -20.7
-69.8
48.1
» NSPH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

NSPH Guru Trades in Q3 2014

John Keeley 26,000 sh (unchged)
George Soros Sold Out
Jim Simons 126,162 sh (-19.57%)
» More
Q4 2014

NSPH Guru Trades in Q4 2014

Jim Simons 284,462 sh (+125.47%)
John Keeley Sold Out
» More
Q1 2015

NSPH Guru Trades in Q1 2015

John Keeley 26,000 sh (New)
Jim Simons 1,046,162 sh (+267.77%)
» More
Q2 2015

NSPH Guru Trades in Q2 2015

Jim Simons 117,103 sh (+123.87%)
John Keeley Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NSPH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 19.46
NSPH's Forward P/E is ranked higher than
53% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.12 vs. NSPH: 19.46 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 0.86
NSPH's P/B is ranked higher than
94% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. NSPH: 0.86 )
Ranked among companies with meaningful P/B only.
NSPH' s 10-Year P/B Range
Min: 0.7  Med: 2.25 Max: 7.34
Current: 0.86
0.7
7.34
P/S 0.81
NSPH's P/S is ranked higher than
89% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.99 vs. NSPH: 0.81 )
Ranked among companies with meaningful P/S only.
NSPH' s 10-Year P/S Range
Min: 0.65  Med: 27.34 Max: 185.74
Current: 0.81
0.65
185.74
Current Ratio 1.70
NSPH's Current Ratio is ranked lower than
70% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.49 vs. NSPH: 1.70 )
Ranked among companies with meaningful Current Ratio only.
NSPH' s 10-Year Current Ratio Range
Min: 0.63  Med: 7.96 Max: 20.13
Current: 1.7
0.63
20.13
Quick Ratio 1.22
NSPH's Quick Ratio is ranked lower than
77% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. NSPH: 1.22 )
Ranked among companies with meaningful Quick Ratio only.
NSPH' s 10-Year Quick Ratio Range
Min: 0.61  Med: 7.21 Max: 19.52
Current: 1.22
0.61
19.52
Days Inventory 386.39
NSPH's Days Inventory is ranked lower than
98% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.75 vs. NSPH: 386.39 )
Ranked among companies with meaningful Days Inventory only.
NSPH' s 10-Year Days Inventory Range
Min: 181.04  Med: 450.65 Max: 5940.08
Current: 386.39
181.04
5940.08
Days Sales Outstanding 70.06
NSPH's Days Sales Outstanding is ranked lower than
57% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. NSPH: 70.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
NSPH' s 10-Year Days Sales Outstanding Range
Min: 14.43  Med: 88.39 Max: 124.07
Current: 70.06
14.43
124.07

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 1.15
NSPH's Price/Net Current Asset Value is ranked higher than
97% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.45 vs. NSPH: 1.15 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NSPH' s 10-Year Price/Net Current Asset Value Range
Min: 0.98  Med: 2.76 Max: 6.95
Current: 1.15
0.98
6.95
Price/Tangible Book 0.86
NSPH's Price/Tangible Book is ranked higher than
94% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.76 vs. NSPH: 0.86 )
Ranked among companies with meaningful Price/Tangible Book only.
NSPH' s 10-Year Price/Tangible Book Range
Min: 0.88  Med: 2.46 Max: 6.09
Current: 0.86
0.88
6.09
Price/Median PS Value 0.03
NSPH's Price/Median PS Value is ranked higher than
99% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. NSPH: 0.03 )
Ranked among companies with meaningful Price/Median PS Value only.
NSPH' s 10-Year Price/Median PS Value Range
Min: 0.04  Med: 0.95 Max: 5.11
Current: 0.03
0.04
5.11
Earnings Yield (Greenblatt) (%) -224.46
NSPH's Earnings Yield (Greenblatt) (%) is ranked lower than
97% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. NSPH: -224.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NSPH' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -434.83  Med: 101.30 Max: 31016.8
Current: -224.46
-434.83
31016.8

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 19 24
EPS($) -4.93 -5.22
EPS without NRI($) -4.93 -5.22

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:3NSN.Germany,
Nanosphere, Inc., was incorporated in 1999 in Delaware. The Company develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene System, that enables sensitive genomic and protein testing on a single platform. The Verigene System includes a bench-top molecular diagnostics workstation that is an advanced platform for genomic and protein testing. The Verigene System includes a bench-top molecular diagnostics workstation that is a universal platform for genomic and protein testing. The Verigene System provides lower cost for laboratories already performing molecular diagnostic testing and enables smaller laboratories and hospitals without advanced diagnostic capabilities to perform genetic testing.
» More Articles for NSPH

Headlines

Articles On GuruFocus.com
Wednesday’s Pre-Market Insights: PBR, SDRL, WDAY, EMC, BLUE May 27 2015 
comment on NSPH Mar 02 2013 
NANOSPHERE, INC. Reports Operating Results (10-Q) Aug 05 2010 
NANOSPHERE, INC. Reports Operating Results (10-Q) May 06 2010 
NANOSPHERE, INC. Reports Operating Results (10-Q) Nov 05 2009 
NANOSPHERE, INC. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
NANOSPHERE INC Financials Aug 22 2015
10-Q/A for Nanosphere, Inc. Aug 13 2015
10-Q for Nanosphere, Inc. Aug 12 2015
Edited Transcript of NSPH earnings conference call or presentation 11-Aug-15 12:30pm GMT Aug 11 2015
Nanosphere Inc Earnings Call scheduled for 8:30 am ET today Aug 11 2015
NANOSPHERE INC Files SEC form 10-Q/A, Quarterly Report Aug 11 2015
NANOSPHERE INC Files SEC form 8-K, Results of Operations and Financial Condition Aug 10 2015
Nanosphere Announces Record Q2 2015 Results Aug 10 2015
Q2 2015 Nanosphere Inc Earnings Release - After Market Close Aug 10 2015
NANOSPHERE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Jul 31 2015
Nanosphere Announces Amendment to $30 Million Term Loan Facility, Release of Q2 2015 Results and... Jul 31 2015
Edited Transcript of NSPH earnings conference call or presentation 12-May-15 12:30pm GMT Jul 20 2015
New Studies Highlight Antibiotic Resistance Detection With Nanosphere's Verigene Blood Culture Tests Jun 22 2015
5 Stocks Under $10 Set to Soar Jun 18 2015
NANOSPHERE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of... Jun 11 2015
NANOSPHERE INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jun 08 2015
Nanosphere Announces $4.4 Million at the Market Registered Direct Offering Jun 08 2015
NANOSPHERE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors... Jun 02 2015
US Military Accidentally Ships Live Anthrax via FedEx; These Are the Stocks to Watch in Its Wake Jun 01 2015
NANOSPHERE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... May 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK